SCHEMBL3786174

SCHEMBL3786174

COC(=O)c1cccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)c1

nearest known ligand 0.85

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MTOR P42345 19/20 0.85
PIK3CA P42336 18/20 0.85
PIK3CD O00329 15/20 0.85
PIK3CB P42338 15/20 0.85
PIK3CG P48736 15/20 0.85
LMNA P02545 1/20 0.53
TP53 P04637 1/20 0.53
TSHR P16473 1/20 0.53
MAPK1 P28482 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3785661 0.92 MTOR (1.00) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL3786430 0.90 MTOR (0.89) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL3782675 0.89 MTOR (0.78) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL7902545 0.85 PIK3CA (0.62) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL3786906 0.85 PIK3CA (0.62) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL9948493 0.85 MTOR (0.78) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL3778668 0.85 MTOR (0.67) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL3787728 0.84 MTOR (1.00) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL3790020 0.84 MTOR (0.74) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL3791094 0.84 MTOR (1.00) MTORPIK3CAPIK3CDPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors AMGEN INC. (US) 2012-06-28 US claimed
EP-2398791-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS Amgen, Inc (US) 2011-12-28 EP claimed
WO-2010096314-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS AMGEN INC. (US) 2010-08-26 WO claimed
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors AMGEN INC. (US) 2012-06-28 US disclosed
EP-2398791-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS Amgen, Inc (US) 2011-12-28 EP disclosed
WO-2010096314-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS AMGEN INC. (US) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors MTOR, PIKFYVE, RICTOR MTOR 1/4885PIK3CA 9/4885PIK3CD 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.